MACROGENICS INC

Listed Company

MGNXCIK 0001125345NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$149.50M

Net Income

$-74.62M

Total Assets

$256.85M

Equity

$55.59M

Shares Out

63.56M

Op. Cash Flow

$-81.04M

MGNX$4.49+191.23% · past yearDBEQ Basic

Daily closing prices

Business

MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer treatment using proprietary DART, TRIDENT, and ADC platforms. The company has three FDA-approved products for which it retains economic rights through royalties and milestone payments, plus three wholly-owned clinical-stage candidates. MacroGenics operates a commercial-scale cGMP manufacturing facility in Maryland, providing contract development and manufacturing services to partners and third parties. The company collaborates with Gilead Sciences on bispecific programs and has received substantial non-dilutive funding from strategic partnerships.

Summary from 10-K filed 2026-03-09

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	150	150	59	152	77
Cost of product sales	0	847,000	619,000	3	3
Cost of manufacturing services	36	11	8	4	0
Research and development	147	177	167	207	215
Selling, general and administrative	39	71	52	59	63
Total costs and expenses	222	261	227	273	280
Loss from operations	−73	−111	−168	−121	−203
Gain on royalty monetization arrangement	0	0	151	0	0
Gain on sale of MARGENZA	0	36	0	0	—
Interest and other income	6	9	10	2	680,000
Interest and other expense	−9	−1	−1	—	—
Loss before income taxes	−75	−66	−9	−120	—
Income tax (benefit) expense	−700,000	944,000	0	0	—
Net loss	−75	−67	−9	−120	−202
Unrealized gain (loss) on investments	28,000	10,000	−1,000	56,000	−54,000
Comprehensive loss	−75	−67	−9	−120	−202
Basic and diluted net loss per common share, basic (in dollars per share)	−1.18	−1.07	−0.15	−1.95	−3.37
Basic and diluted net loss per common share, diluted (in dollars per share)	−1.18	−1.07	−0.15	−1.95	−3.37
Basic weighted average number of common shares outstanding (in shares)	63	63	62	61	60
Diluted weighted average number of common shares outstanding (in shares)	63	63	62	61	60

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	57	183	101	109	123
Marketable securities	133	19	129	46	120
Accounts receivable	13	4	10	56	10
Inventory, net	8	0	1	1	4
Prepaid expenses and other current assets	9	12	10	10	21
Total current assets	220	217	251	222	280
Property, equipment and software, net	13	18	22	30	38
Operating lease right-of-use assets	23	25	24	27	17
Other non current assets	1	2	1	1	1
Total assets	257	262	298	280	335
Accounts payable	5	5	6	5	16
Accrued expenses and other current liabilities	22	29	24	29	34
Deferred revenue	11	16	22	10	21
Lease liabilities	5	5	4	5	5
Total current liabilities	43	56	56	49	75
Liability related to future royalties	70	0	—	—	—
Deferred revenue, net of current portion	56	56	59	59	0
Lease liabilities, net of current portion	32	33	30	30	21
Other non current liabilities	1	2	258,000	258,000	258,000
Total liabilities	201	146	146	138	96
Common stock, 0.01 par value -- 125,000,000 shares authorized, 63,318,613 and 62,819,857 shares outstanding at December 31, 2025 and December 31, 2024, respectively	633,000	628,000	621,000	617,000	613,000
Additional paid-in capital	1,299	1,285	1,255	1,235	1,213
Accumulated other comprehensive gain	32,000	4,000	−6,000	−5,000	−61,000
Accumulated deficit	−1,244	−1,170	−1,103	−1,094	−974
Total stockholders' equity	56	116	153	142	240
Total liabilities and stockholders' equity	257	262	298	280	335

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	7	8	10	12	11
Amortization of premiums and discounts on marketable securities	−2	−3	−5	403,000	2
Share-based compensation	14	29	18	20	23
Non-cash royalty revenue	−8	0	0	—	—
Non-cash interest expense	8	0	1	0	0
Non-cash lease expense	2	−663,000	3	3	3
Other non-cash items	0	2,000	423,000	3	2
(Gain) loss on disposal of assets	−10,000	−57,000	111,000	0	0
Accounts receivable	−9	6	46	−46	13
Inventory	−8	−2	230,000	55,000	−6
Prepaid expenses and other current assets	3	−2	215,000	11	−4
Other non current assets	0	−170,000	−7,000	−14	3
Accounts payable	−280,000	−2	1	−11	7
Accrued expenses and other current liabilities	−7	5	−5	−5	−607,000
Lease liabilities	−699,000	3	−861,000	9	−4
Deferred revenue	−5	−9	11	49	9
Other non current liabilities	−916,000	2	0	0	—
Net cash used in operating activities	−81	−68	−78	−87	−144
Purchases of marketable securities	−208	−77	−240	−121	−231
Proceeds from sales and maturities of marketable securities	96	190	161	195	201
Purchases of property, equipment and software	−2	−4	−2	−4	−6
Proceeds from sale of MARGENZA	0	40	0	0	—
Proceeds from sales of equipment	11,000	160,000	64,000	0	0
Net cash provided by (used in) investing activities	−114	149	−80	71	−37
Proceeds from issuance of common stock, net of offering costs	0	0	616,000	1	118
Proceeds from stock option exercises and ESPP purchases	129,000	3	553,000	574,000	5
Taxes paid related to net share settlement of equity awards	−288,000	−2	−306,000	0	—
Principal payments on royalty monetization arrangement	0	0	−157,000	0	0
Net proceeds from sale of future royalties	70	0	150	0	0
Net cash provided by financing activities	70	960,000	150	2	123
Net change in cash and cash equivalents	−126	82	−8	−15	−58
Property and equipment included in accounts payable or accruals	54,000	100,000	505,000	118,000	508,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is MACROGENICS INC's CIK number?

MACROGENICS INC's SEC CIK number is 0001125345 (1125345). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find MACROGENICS INC's SEC filings?

All of MACROGENICS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did MACROGENICS INC last report earnings?

MACROGENICS INC (MGNX) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001125345-26-000040). This is MACROGENICS INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is MACROGENICS INC's most recent earnings 8-K?

MACROGENICS INC's latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001125345-26-000040. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View MACROGENICS INC's latest earnings 8-K →
Look up any company's CIK number →